Can a website help women decide on breast cancer screening?

NCT ID NCT05607849

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

This French trial tests whether a decision aid leaflet and website help women make informed choices about organized breast cancer screening. It includes women aged 50 to 74 who are invited for screening and their general practitioners. Researchers measure decisional conflict and intention to participate two months after women receive the tool.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a decision aid leaflet and website about breast cancer screening
What this could lead to
If it works, this could give women clearer information and more confidence when deciding whether to join breast cancer screening.
What could go wrong
The tool may not change how women decide, and the results may not apply outside France. The study does not test whether screening itself saves lives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20,000 people

The number who actually took part.

Started

Apr 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 74 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : \- General practitioners (GPs): The following GPs will be included: 1\) Practicing in one of the French départements (administrative area) covered by the study. \- Women: The following women will be included: 1. Invited to participate in OBCS by the National Health Insurance Agency (Caisse Nationale d'Assurance Maladie; CNAM) during the studied month: eligible for OBCS, therefore aged between 50 and 74 at the time of inclusion; 2. On the patient list of a GP who is covered by the study at the time of inclusion; 3. Covered by one of the CPAM (Caisse Primaire d'Assurance Maladie) in the participating departments. Exclusion Criteria : \- General practitioners (GPs) : The following GPs will be excluded: 1. Those who do not have any patients invited for OBCS in the studied month; 2. Those whose practice does not correspond to the usual activities of a GP (known as a Mode d'Exercice Particulier), or who have very few patients (who have seen fewer than 100 different patients in the year preceding the experiment); 3. Those who practice within a health centre (as it is impossible to evaluate the activity of an individual practitioner in health insurance databases); 4. Those who explicitly state that they do not want to take part in the study, in response to an initial letter of invitation. This letter will inform them that the study is being run, and will inform them of the option to refuse to participate if they so wish; 5. Those who are participating in the MyPEBS study (the only national study of OBCS at the time the present protocol was drawn up). * Women: The following women will not be included: 1. Participants in the MyPEBS study ( the only national study of OBCS at the time the present protocol was drawn up); or, 2. If their GP refuses to participate in the study; or, 3. women under guardianship. The following women will be excluded: * Those who object to the study in accordance with regulatory procedures issued by the Data Protection Officer (DPO), * Those who do not respond within 1 month after the questionnaire has been sent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.